RxDoctor Payments Data

Elaina Vayntrub, MD

Internal Medicine · Ypsilanti, MINPI 1770573958

Payments from drug & device makers

$22,233in general payments, 2019–2025

Across 170 payments — averaging $130.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$20K
  • Novo Nordisk$1K
  • Amgen$263
  • Ascendis Pharma Endocrinology Inc$121
  • Acelrx Pharmaceuticals, Inc.$110
  • Endo Pharmaceuticals Inc.$70
  • plus $281 from 9 others

What the payments were for

  • Consulting fees$4,02518%
  • Speaking & faculty fees$13,65061%
  • Travel & lodging$2,17410%
  • Food & beverage$2,34011%
  • Education$440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,233 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$48,774
Medicare patients
172
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide394$433,030
OzempicSemaglutide100$123,503
Teriparatide36$87,237
WegovySemaglutide58$84,934
ArexvyRsvpref3 Antigen/As01e/Pf52$15,584
LinzessLinaclotide22$12,316
ShingrixVaricella-Zoster Ge/As01b/Pf55$11,724
TrulicityDulaglutide12$11,285
Dexlansoprazole DrDexlansoprazole11$1,352
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf15$1,040
Topiramate82$684
Bupropion Hcl SrBupropion Hcl16$456
Nystatin23$312
Simvastatin44$305
Ondansetron Hcl50$274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$20,295$444,315406 claims
Novo NordiskOzempic, Wegovy$1,093$208,437158 claims
Alvogen IncTeriparatide$35$87,23736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Ypsilanti

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →